CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced the advance online publication by CombinatoRx scientists of an extensive analysis of their discovery screening, scheduled to appear in the August issue of Nature Biotechnology. These new findings provide evidence that multi-target synergistic combinations may be more therapeutically specific than single agents.
